Trial Profile
A Phase 1 Study of Neratinib (HKI-272) in Combination With Paclitaxel in Subjects With Solid Tumours.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Nov 2018
Price :
$35
*
At a glance
- Drugs Neratinib (Primary) ; Paclitaxel
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Puma Biotechnology
- 11 May 2012 Company (Puma Biotechnology) added as reported by ClinicalTrials.gov.
- 28 Jan 2011 Actual end date (January 2011) added as reported by ClinicalTrials.gov.
- 28 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.